Table 3.

Real-world effectiveness of palbociclib–summary of evidence available

References	Design	Follow-up	Setting	n	Results
Torres et al. [27]	Retrospective multicentric cohort study	Median: 19.4 months	First line (palbo + AI)	878	Median PFS: 21.9 months (95%CI 20.1–28.2)
Varella et al. [15]	Retrospective single-center cohort study	Median: 10.2 months	First line (palbo + AI)	57	Median PFS: 15.1 months (95%CI 12.3-NR)
Taylor-Stokes et al. [18]	Retrospective multicentric cohort study	Mean: 9.9 months (SD 5.2)	First line (palbo + AI)	360	PFS at 12 months: 84.1% OS at 12 months: 95.1%
Wilkie et al. [16]	Retrospective single-center cohort study	Not available	First line (palbo + AI)	70	Median PFS: 26.4 months (95%CI 19.7–33.2)
Waller et al. [19]	Retrospective multicentric cohort study	Mean: 10 months (SD 4)	First line (palbo + AI)	105	PFS at 6 months: 94.0% OS at 6 months: 98.0%
DeMichelle et al.[25]	Retrospective multicentric cohort study	Mean: 24.2 months (IQR, 14.2–34.9)	First line (palbo + AI)	1430	Median PFS: 20.0 months OS not reached
Palumbo et al. [26]	Prospective multicentric cohort study	Mean: 24 months (range 6–32)	First line (palbo + AI)	182	Median PFS: 14.0 months Median OS: 25.0 months

Palbo + AI, Palbociclib in association with an aromatase inhibitor; SD, Standard deviation; IQR, interquartile range; NR, not reached